A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)
- Conditions
- Colorectal Cancer
- Interventions
- Registration Number
- NCT05064059
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Brief Summary
The purpose of this study is to assess the safety and efficacy of coformulated favezelimab/pembrolizumab (MK-4280A) in participants with metastatic colorectal cancer. The study will also compare MK-4280A with the standard of care treatment of regorafenib and TAS-102 (trifluridine and tipiracil).
The primary study hypothesis is that coformulated favezelimab/pembrolizumab (MK-4280A) is superior to standard of care with respect to overall survival.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 441
- Has a histologically confirmed colorectal adenocarcinoma that is metastatic and unresectable.
- Has measurable disease per RECIST 1.1 as assessed by the local site investigator.
- Has been previously treated for the disease and radiographically progressed on or after or could not tolerate standard treatment.
- Submits an archival (≤ 5 years) or newly obtained tumor tissue sample or newly obtained tumor tissue sample that has not been previously irradiated.
- Has an Eastern Cooperative Oncology Group Performance Score (ECOG PS) of 0 to 1 within 10 days prior to first dose of study intervention.
- Has a life expectancy of at least 3 months, based on the investigator assessment.
- Has the ability to swallow and retain oral medication and not have any clinically significant gastrointestinal abnormalities that might alter absorption.
- Has adequate organ function.
- Has previously been found to have deficient mismatch repair/microsatellite instability-high (dMMR/MSI-H) tumor status.
- Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis or leptomeningeal disease.
- Has a history of acute or chronic pancreatitis.
- Has neuromuscular disorders associated with an elevated creatine kinase (eg, inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis, spinal muscular atrophy).
- Has clinically significant cardiovascular disease within 12 months from first dose of study intervention, including New York Heart Association Class III or IV congestive heart failure, unstable angina, myocardial infarction, cerebral vascular accident, or cardiac arrhythmia associated with hemodynamic instability.
- Has urine protein greater than or equal to 1g/24h.
- A woman of childbearing potential who has a positive urine/serum pregnancy test within 24/72 hours prior to the first dose of study intervention.
- Has received prior therapy with an anti-programmed cell death 1 (PD-1), anti-programmed death ligand 1 (PD-L1), or anti-programmed cell death ligand 2 (PD-L2), anti-lymphocyte activation gene 3 (LAG-3) antibody, with a tyrosine kinase inhibitor (TKI; eg, lenvatinib) other than rapidly accelerated fibrosarcoma (RAF) inhibitors (binimetinib is permitted if combined with a RAF inhibitor), or with an agent directed to another stimulatory or coinhibitory T-cell receptor (eg, cytotoxic T-lymphocyte-associated protein 4, OX-40, cluster of differentiation [CD] 137).
- Has previously received regorafenib or TAS-102.
- Has received prior systemic anticancer therapy including investigational agents within 28 days before randomization.
- Has received prior radiotherapy within 2 weeks of start of study intervention. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease.
- Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention.
- Has a known additional malignancy that is progressing or has required active treatment within the past 3 years.
- Has severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients.
- Has an active autoimmune disease that has required systemic treatment in past 2 years.
- Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.
- Has an active infection requiring systemic therapy (eg, tuberculosis, known viral or bacterial infections, etc.).
- Has a known history of human immunodeficiency virus (HIV) infection.
- Has known history of Hepatitis B or known active Hepatitis C virus infection.
- Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator.
- Has had an allogenic tissue/solid organ transplant.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Favezelimab/Pembrolizumab favezelimab/pembrolizumab Participants will receive coformulated favezelimab/pembrolizumab (800 mg/200 mg) intravenously (IV) on Day 1, then every 3 weeks (Q3W), for up to 35 infusions. Standard of Care (Regorafenib or TAS-102) regorafenib At the Investigator's choice, participants will receive 160 mg regorafenib orally daily on Days 1-12 of each 28-day cycle or 35 mg/m\^2 TAS-102 orally twice daily on Days 1-5 and Days 8-12 of each 28-day cycle. Standard of Care (Regorafenib or TAS-102) TAS-102 At the Investigator's choice, participants will receive 160 mg regorafenib orally daily on Days 1-12 of each 28-day cycle or 35 mg/m\^2 TAS-102 orally twice daily on Days 1-5 and Days 8-12 of each 28-day cycle.
- Primary Outcome Measures
Name Time Method Overall Survival (OS) Up to approximately 26 months OS is defined as the time from randomization to death due to any cause.
- Secondary Outcome Measures
Name Time Method Objective Response Rate (ORR) per RECIST 1.1 as Assessed by BICR Up to approximately 19 months The ORR is defined as the percentage of participants who achieve a confirmed complete response (CR) or partial response (PR) per RECIST 1.1 as assessed by BICR.
Duration of Response (DOR) per RECIST 1.1 as Assessed by BICR Up to approximately 19 months For participants who demonstrate confirmed CR or PR, duration of response is defined as the time from the first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurs first.
Number of Participants Who Discontinue Study Treatment Due to an AE Up to approximately 24 months An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE will be reported.
Progression-Free Survival (PFS) according per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR) Up to approximately 19 months PFS is defined as the time from randomization to the first documented disease progression per RECIST 1.1 by BICR or death due to any cause, whichever occurs first.
Number of Participants Who Experience at least One Adverse Event (AE) Up to approximately 27 months An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Time to Deterioration (TTD) in EORTC QLQ-C30 GHS (Item 29) and QoL (Item 30) Combined Score Baseline and up to approximately 25 months TTD is defined as the time from baseline to the first onset of a ≥10-point deterioration (decrease) from baseline in GHS (EORTC QLQ-C30 Item 29) \& QoL combined score (EORTC QLQ-C30 Item 30). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The TTD, as assessed based on a ≥10-point negative change (decrease) from baseline in GHS and QoL combined score, will be presented. A longer TTD indicates a better outcome.
TTD in EORTC QLQ-C30 Physical Functioning (Items 1-5) Combined Score Baseline and up to approximately 25 months TTD is defined as the time from baseline to the first onset of a ≥10-point deterioration (decrease) from baseline in physical functioning score (EORTC QLQ-C30 Items 1-5). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The TTD, as assessed based on a ≥10-point negative change (decrease) from baseline in GHS and QoL combined score, will be presented. A longer TTD indicates a better outcome.
TTD in in EORTC QLQ-C30 Appetite Loss (Item 13) Score Baseline and up to approximately 25 months TTD is defined as the time from baseline to the first onset of a ≥10-point deterioration (decrease) from baseline in appetite loss score (EORTC QLQ-C30 Item 13). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The TTD, as assessed based on a ≥10-point negative change (decrease) from baseline in physical functioning score, will be presented. A longer TTD indicates a better outcome.
TTD in EORTC Quality of Life Questionnaire-Colorectal Cancer-Specific 29 Items (QLQ-CR29) Bloating (Item 37) Score Baseline and up to approximately 25 months TTD is defined as the time from baseline to the first onset of a ≥10-point deterioration (decrease) from baseline in bloating score (QLQ-CR29 Item 37). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The TTD, as assessed based on a ≥10-point negative change (decrease) from baseline in appetite loss score, will be presented. A longer TTD indicates a better outcome.
Change from Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status (Item 29) and Quality of Life (Item 30) Combined Score Baseline and up to approximately 25 months The EORTC QLQ-C30 is a cancer specific health-related quality-of life (QoL) questionnaire. Participant responses to the questions regarding Global Health Status (GHS; "How would you rate your overall health during the past week?") and Quality of Life (QoL; "How would you rate your overall quality of life during the past week?") are scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The change from baseline in GHS (EORTC QLQ-C30 Item 29) and QoL (EORTC QLQ-C30 Item 30) combined score will be presented. A higher score indicates a better outcome.
Change from Baseline in EORTC QLQ-C30 Physical Functioning (Items 1-5) Score Baseline and up to approximately 25 months The EORTC QLQ-C30 is a cancer specific health-related quality-of life (QoL) questionnaire. Participant responses to 5 questions about their physical functioning (Items 1-5) are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. Higher scores meant a better level of function.
Change from Baseline in EORTC QLQ-C30 Appetite Loss (Item 13) Score Baseline and up to approximately 25 months The EORTC QLQ-C30 is a cancer specific health-related quality-of life (QoL) questionnaire, including a single-item scale score for appetite loss (QLQ-C30 Item 13). For this item, individual responses to the question "Have you lacked appetite?" are given on a 4-point scale (1=Not at all; 4=Very much). Scores are transformed to a range from 0-100, with a lower score indicating a better outcome. The change from baseline in the EORTC QLQ-C30 appetite loss (Item 13) scale score will be presented.
Change from Baseline in EORTC Quality of Life Questionnaire-Colorectal Cancer-Specific 29 Items (QLQ-CR29) Bloating (Item 37) Score Baseline and up to approximately 25 months The EORTC QLQ-CR29 is a health-related quality-of life (QoL) questionnaire specific for colorectal cancer, including a single-item scale score for bloating (QLQ-CR29 Item 37). For this item, individual responses to the question "Did you have a bloated feeling in your abdomen?" are given on a 4-point scale (1=Not at all; 4=Very much). Scores are transformed to a range from 0-100, with a lower score indicating a better outcome. The change from baseline in the EORTC QLQ-CR29 bloating (Item 37) scale score will be presented.
Trial Locations
- Locations (152)
Fujian Province Cancer Hospital ( Site 1178)
🇨🇳Fuzhou, Fujian, China
Guangxi Medical University Affiliated Tumor Hospital ( Site 1158)
🇨🇳Nanning, Guangxi, China
Wuhan Union Hospital Cancer Center ( Site 1162)
🇨🇳Wuhan, Hubei, China
Hubei Cancer Hospital ( Site 1152)
🇨🇳Wuhan, Hubei, China
Xiangya Hospital Central South University ( Site 1171)
🇨🇳Changsha, Hunan, China
Changzhou Cancer Hospital-Department of Oncology ( Site 1183)
🇨🇳Changzhou, Jiangsu, China
Zhejiang Cancer Hospital ( Site 1180)
🇨🇳Hangzhou, Zhejiang, China
Jinan Central Hospital ( Site 1167)
🇨🇳Jinan, Shandong, China
Fudan University Shanghai Cancer Center ( Site 1176)
🇨🇳Shangai, Shanghai, China
West China Hospital Sichuan University ( Site 1172)
🇨🇳Chengdu, Sichuan, China
Baskent Universitesi Dr. Turgut Noyan Uygulama ve Arastirma Merkezi ( Site 1007)
🇹🇷Adana, Turkey
Acibadem Adana Hastanesi ( Site 1008)
🇹🇷Adana, Turkey
Gulhane Egitim ve Arastirma Hastanesi ( Site 1009)
🇹🇷Ankara, Turkey
Ege Universitesi Tip Fakultesi Hastanesi ( Site 1006)
🇹🇷Izmir, Turkey
Rutgers Cancer Institute of New Jersey ( Site 1105)
🇺🇸New Brunswick, New Jersey, United States
Blue Ridge Cancer Care ( Site 1718)
🇺🇸Roanoke, Virginia, United States
Royal Brisbane and Women s Hospital ( Site 0058)
🇦🇺Herston, Queensland, Australia
Seattle Cancer Care Alliance ( Site 1107)
🇺🇸Seattle, Washington, United States
Western Health-Sunshine & Footscray Hospitals ( Site 0052)
🇦🇺St Albans, Victoria, Australia
Chongqing Cancer Hospital ( Site 1151)
🇨🇳Chongqing, Chongqing, China
Sun Yat-Sen University Cancer Center ( Site 1150)
🇨🇳Guangzhou, Guangdong, China
St John of God Subiaco Hospital ( Site 0051)
🇦🇺Perth, Western Australia, Australia
Jilin Cancer Hospital ( Site 1163)
🇨🇳Changchun, Jilin, China
Katholisches Marienkrankenhaus gGmbH ( Site 1257)
🇩🇪Hamburg, Germany
Fakultni Thomayerova nemocnice ( Site 1205)
🇨🇿Praha 4, Czechia
Fakultni nemocnice Hradec Kralove ( Site 1207)
🇨🇿Hradec Kralove, Czechia
LMU Klinikum Grosshadern der Universitaet Muenchen ( Site 1253)
🇩🇪Muenchen, Bayern, Germany
Bnei Zion Medical Center ( Site 0506)
🇮🇱Haifa, Israel
Assuta Ashdod Public ( Site 0507)
🇮🇱Ashdod, Israel
Hadassa Ein Karem Medical Center ( Site 0504)
🇮🇱Jerusalem, Israel
Chaim Sheba Medical Center ( Site 0501)
🇮🇱Ramat Gan, Israel
Hopital Europeen Georges Pompidou ( Site 0300)
🇫🇷Paris, France
Tianjin Medical University Cancer Institute and Hospital ( Site 1161)
🇨🇳Tianjin, Tianjin, China
Yunnan Province Cancer Hospital-Colorectal surgery ( Site 1169)
🇨🇳Kunming, Yunnan, China
Fakultni nemocnice Kralovske Vinohrady ( Site 1208)
🇨🇿Praha 10, Czechia
Klinikum Wolfsburg ( Site 1256)
🇩🇪Wolfsburg, Niedersachsen, Germany
Masarykuv onkologicky ustav ( Site 1203)
🇨🇿Brno, Brno-mesto, Czechia
Philipps-Universitaet Marburg. ( Site 1252)
🇩🇪Marburg, Hessen, Germany
Kliniken Maria Hilf GmbH ( Site 1255)
🇩🇪Moenchengladbach, Nordrhein-Westfalen, Germany
Rambam Health Care Campus-Oncology Division ( Site 0500)
🇮🇱Haifa, Israel
Fakultni nemocnice v Motole ( Site 1201)
🇨🇿Praha, Praha, Hlavni Mesto, Czechia
Universita degli Studi della Campania Luigi Vanvitelli-UOC Oncoematologia ( Site 0556)
🇮🇹Napoli, Italy
A.O. di Rilievo Nazionale e di alta Specializzazione Garibaldi ( Site 0553)
🇮🇹Catania, Italy
Japanese Foundation for Cancer Research ( Site 0602)
🇯🇵Tokyo, Japan
Oslo Universitetssykehus HF. Ulleval ( Site 1351)
🇳🇴Oslo, Norway
Seoul National University Hospital ( Site 0653)
🇰🇷Seoul, Korea, Republic of
Republican Clinical Oncology Dispensary of Republic of Bashkortostan ( Site 0871)
🇷🇺Ufa, Baskortostan, Respublika, Russian Federation
Severance Hospital ( Site 0652)
🇰🇷Seoul, Korea, Republic of
Kagawa University Hospital ( Site 0608)
🇯🇵Kita-gun, Kagawa, Japan
Tomsk National Research Medical Center of Russian Academy of Sciences ( Site 0872)
🇷🇺Tomsk, Tomskaya Oblast, Russian Federation
National Cancer Center Hospital East ( Site 0600)
🇯🇵Kashiwa, Chiba, Japan
National Cancer Center Hospital ( Site 0601)
🇯🇵Tokyo, Japan
Asan Medical Center ( Site 0650)
🇰🇷Songpagu, Seoul, Korea, Republic of
Hospital Universitari Vall d Hebron ( Site 0900)
🇪🇸Barcelona, Spain
Royal Marsden NHS Trust ( Site 1063)
🇬🇧Sutton, London, City Of, United Kingdom
National Cheng Kung University Hospital ( Site 0955)
🇨🇳Tainan, Taiwan
Hospital Clinico San Carlos ( Site 0902)
🇪🇸Madrid, Spain
Yaroslavl Regional SBIH Clinical Oncology Hospital ( Site 0850)
🇷🇺Yaroslavl, Yaroslavskaya Oblast, Russian Federation
Goztepe Prof.Dr. Suleyman Yalcin Sehir Hastanesi ( Site 1002)
🇹🇷Istanbul, Turkey
University Hospital Coventry & Warwickshire ( Site 1062)
🇬🇧Coventry, Warwickshire, United Kingdom
University College London Hospitals NHS Foundation Trust ( Site 1056)
🇬🇧London, Camden, United Kingdom
Royal Marsden NHS Foundation Trust ( Site 1064)
🇬🇧London, London, City Of, United Kingdom
London Regional Cancer Program - London HSC ( Site 0154)
🇨🇦London, Ontario, Canada
FSBI-FRCC of Special Types Med. Care and Technologies FMBA of Russia ( Site 0851)
🇷🇺Moscow, Moskva, Russian Federation
Queen Elizabeth Hospital ( Site 0050)
🇦🇺Woodville South, South Australia, Australia
Sibley Memorial Hospital ( Site 1143)
🇺🇸Washington, District of Columbia, United States
Georgetown University Hospital ( Site 1148)
🇺🇸Washington, District of Columbia, United States
Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research ( Site 1118)
🇺🇸Marietta, Georgia, United States
Memorial Sloan Kettering Cancer Center ( Site 1703)
🇺🇸New York, New York, United States
Oregon Health & Science University ( Site 1141)
🇺🇸Portland, Oregon, United States
The West Clinic, PLLC dba West Cancer Center ( Site 1149)
🇺🇸Germantown, Tennessee, United States
Intermountain Medical Center ( Site 1707)
🇺🇸Murray, Utah, United States
UT Southwestern Medical Center ( Site 1709)
🇺🇸Dallas, Texas, United States
Frankston Hospital ( Site 0056)
🇦🇺Frankston, Victoria, Australia
Westmead Hospital ( Site 0057)
🇦🇺Westmead, New South Wales, Australia
IC La Serena Research ( Site 0202)
🇨🇱La Serena, Coquimbo, Chile
Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 0155)
🇨🇦Toronto, Ontario, Canada
Centro Investigacion Cancer James Lind ( Site 0204)
🇨🇱Temuco, Araucania, Chile
Clinica Puerto Montt ( Site 0211)
🇨🇱Puerto Montt, Los Lagos, Chile
Fundacion Arturo Lopez Perez FALP ( Site 0208)
🇨🇱Santiago, Region M. De Santiago, Chile
Pontificia Universidad Catolica de Chile ( Site 0206)
🇨🇱Santiago, Region M. De Santiago, Chile
The Second Affiliated Hospital of Anhui Medical University ( Site 1179)
🇨🇳Hefei, Anhui, China
Hunan Cancer Hospital ( Site 1174)
🇨🇳Changsha, Hunan, China
Hainan General Hospital ( Site 1177)
🇨🇳Haikou, Hainan, China
The Third Xiangya Hospital of Central South University ( Site 1175)
🇨🇳Changsha, Hunan, China
Shanghai Tenth People's Hospital ( Site 1170)
🇨🇳Shanghai, Shanghai, China
Affiliated Hospital of Jiangnan University(Wuxi Fourth People's Hospital ) ( Site 1185)
🇨🇳Wuxi City, Jiangsu, China
Sir Run Run Shaw Hospital-Medical Oncology ( Site 1173)
🇨🇳Hangzhou, Zhejiang, China
Fakultni nemocnice Na Bulovce ( Site 1202)
🇨🇿Praha 8, Czechia
CHU Bordeaux Haut-Leveque ( Site 0305)
🇫🇷Pessac, Gironde, France
Institut du Cancer Avignon-Provence ( Site 0306)
🇫🇷Avignon, Vaucluse, France
Johanniter Krankenhaus Bonn ( Site 1254)
🇩🇪Bonn, Nordrhein-Westfalen, Germany
Universitätsklinikum Halle ( Site 1251)
🇩🇪Halle (Saale), Sachsen-Anhalt, Germany
Rabin Medical Center ( Site 0503)
🇮🇱Petah Tikva, Israel
Sourasky Medical Center ( Site 0502)
🇮🇱Tel Aviv, Israel
Istituto Clinico Humanitas - Cancer Center ( Site 0555)
🇮🇹Rozzano, Milano, Italy
IRCCS Casa Sollievo della Sofferenza ( Site 0554)
🇮🇹San Giovanni Rotondo, Foggia, Italy
ASST Grande Ospedale Metropolitano Niguarda ( Site 0550)
🇮🇹Milano, Italy
Kindai University Hospital ( Site 0607)
🇯🇵Osakasayama, Osaka, Japan
Saitama Prefectural Cancer Center ( Site 0603)
🇯🇵Kitaadachi-gun, Saitama, Japan
Institut Kanser Negara - National Cancer Institute ( Site 1302)
🇲🇾Putrajaya, Wilayah Persekutuan Putrajaya, Malaysia
Shizuoka Cancer Center ( Site 0605)
🇯🇵Sunto-gun,, Shizuoka, Japan
Samsung Medical Center ( Site 0651)
🇰🇷Seoul, Korea, Republic of
Akershus universitetssykehus ( Site 1352)
🇳🇴Loerenskog, Akershus, Norway
Helse Bergen HF - Haukeland univeritetssykehus ( Site 1353)
🇳🇴Bergen, Vestfold, Norway
St Olavs Hospital ( Site 1354)
🇳🇴Trondheim, Sor-Trondelag, Norway
SRBHI of Kirov Region Center of Oncology and medical radiology ( Site 0854)
🇷🇺Kirov, Kirovskaya Oblast, Russian Federation
Main Military Clinical Hospital n.a. N.N.Burdenko ( Site 0870)
🇷🇺Moscow, Moskva, Russian Federation
City Hospital #40 ( Site 0853)
🇷🇺Saint Petersburg, Sankt-Peterburg, Russian Federation
SHBI "Leningrad Regional Clinical Oncology Dispensary n.a. L.D. Roman"-Clinical Trials Department (
🇷🇺Sankt-Peterburg, Russian Federation
Clinical Research Center of specialized types medical care-Oncology ( Site 0860)
🇷🇺Saint-Petersburg, Sankt-Peterburg, Russian Federation
Hospital Universitario Virgen Macarena ( Site 0906)
🇪🇸Sevilla, Spain
Sandton Oncology Medical Group PTY LTD ( Site 1501)
🇿🇦Sandton, Gauteng, South Africa
Cancer Care Langenhoven Drive Oncology Centre ( Site 1504)
🇿🇦Port Elizabeth, Eastern Cape, South Africa
Cancercare Rondebosch Oncology ( Site 1509)
🇿🇦Rondebosch, Western Cape, South Africa
Hospital Sant Pau i la Santa Creu ( Site 0905)
🇪🇸Barcelona, Spain
Hospital Universitario 12 de Octubre ( Site 0901)
🇪🇸Madrid, Spain
Taipei Veterans General Hospital ( Site 0951)
🇨🇳Taipei, Taiwan
Hacettepe Universitesi Tip Fakultesi ( Site 1003)
🇹🇷Ankara, Turkey
Ankara Sehir Hastanesi ( Site 1005)
🇹🇷Ankara, Turkey
Ukrainian Center of Tomotherapy ( Site 1658)
🇺🇦Kropyvnytskyi, Kirovohradska Oblast, Ukraine
Antalya Egitim ve Arastirma Hastanesi ( Site 1010)
🇹🇷Antalya, Turkey
Municipal Non-Profit Enterprise City Clinical Hospital 4 of Dnipro City Council ( Site 1657)
🇺🇦Dnipro, Dnipropetrovska Oblast, Ukraine
MI Precarpathian Clinical Oncology Center ( Site 1654)
🇺🇦Ivano-Frankivsk, Ivano-Frankivska Oblast, Ukraine
Imperial College Healthcare NHS Trust - Hammersmith Hospital ( Site 1052)
🇬🇧London, London, City Of, United Kingdom
Velindre Cancer Centre ( Site 1058)
🇬🇧Cardiff, United Kingdom
Leeds Teaching Hospitals NHS Trust ( Site 1050)
🇬🇧Leeds, United Kingdom
Fakultni nemocnice Olomouc ( Site 1204)
🇨🇿Olomouc, Czechia
Inova Schar Cancer Institute ( Site 1130)
🇺🇸Fairfax, Virginia, United States
National Hospital Organization Kyushu Cancer Center ( Site 0609)
🇯🇵Fukuoka, Japan
The Ottawa Hospital ( Site 0151)
🇨🇦Ottawa, Ontario, Canada
Norton Cancer Institute ( Site 1139)
🇺🇸Louisville, Kentucky, United States
MUSC Hollings Cancer Center ( Site 1715)
🇺🇸Charleston, South Carolina, United States
Policlinico Gemelli di Roma ( Site 0552)
🇮🇹Roma, Abruzzo, Italy
Cape Town Oncology Trials Pty Ltd ( Site 1506)
🇿🇦Kraaifontein, Western Cape, South Africa
Oncovida ( Site 0209)
🇨🇱Santiago, Region M. De Santiago, Chile
Bradfordhill ( Site 0200)
🇨🇱Santiago, Region M. De Santiago, Chile
University Malaya Medical Centre ( Site 1301)
🇲🇾Kuala Lumpur, Malaysia
CHU Hotel Dieu Nantes ( Site 0303)
🇫🇷Nantes, Pays-de-la-Loire, France
Beacon Hospital Sdn Bhd ( Site 1305)
🇲🇾Petaling Jaya, Selangor, Malaysia
Pantai Hospital Kuala Lumpur ( Site 1303)
🇲🇾Bangsar, Kuala Lumpur, Malaysia
Universitetssykehuset i Nord Norge. ( Site 1355)
🇳🇴Tromsoe, Troms, Norway
China Medical University Hospital ( Site 0953)
🇨🇳Taichung, Taiwan
Odessa Regional Clinical Hospital ( Site 1664)
🇺🇦Odesa, Odeska Oblast, Ukraine
Clínica Vespucio ( Site 0205)
🇨🇱Santiago, Region M. De Santiago, Chile
CHU Poitiers ( Site 0304)
🇫🇷Poitiers, Vienne, France
Chang Gung Medical Foundation - Kaohsiung ( Site 0956)
🇨🇳Kaohsiung, Changhua, Taiwan
Chang Gung Medical Foundation. Linkou ( Site 0952)
🇨🇳Taoyuan, Taiwan
National Taiwan University Hospital ( Site 0950)
🇨🇳Taipei, Taiwan
VCU Health Adult Outpatient Pavillion ( Site 1712)
🇺🇸Richmond, Virginia, United States
Southern Medical University Nanfang Hospital ( Site 1154)
🇨🇳Guangzhou, Guangdong, China
The Sixth Affiliated Hospital of Sun Yat-sen University ( Site 1159)
🇨🇳Guangzhou, Guangdong, China